Shares of uniQure (NASDAQ:QURE - Get Free Report) have earned an average rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $19.50.
A number of analysts recently weighed in on QURE shares. HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, August 20th. StockNews.com upgraded shares of uniQure to a "sell" rating in a research note on Thursday, October 17th. The Goldman Sachs Group increased their price target on shares of uniQure from $6.00 to $10.00 and gave the stock a "neutral" rating in a research note on Friday, August 2nd. Raymond James restated an "outperform" rating and set a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $28.00 price objective on shares of uniQure in a research report on Friday, September 20th.
Check Out Our Latest Analysis on uniQure
Shares of uniQure stock opened at $6.54 on Friday. The company has a fifty day simple moving average of $5.74 and a 200-day simple moving average of $5.71. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. The stock has a market cap of $318.25 million, a price-to-earnings ratio of -1.10 and a beta of 0.95.
uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.08. The business had revenue of $11.13 million during the quarter, compared to analysts' expectations of $3.47 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. On average, equities analysts forecast that uniQure will post -4.1 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. abrdn plc increased its holdings in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company's stock valued at $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Vanguard Group Inc. grew its stake in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company's stock valued at $5,577,000 after acquiring an additional 109,740 shares during the last quarter. BNP Paribas Financial Markets grew its stake in uniQure by 4.3% in the 1st quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company's stock valued at $3,831,000 after acquiring an additional 30,054 shares during the last quarter. Privium Fund Management B.V. grew its stake in uniQure by 10.6% in the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company's stock valued at $2,869,000 after acquiring an additional 61,501 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in uniQure by 133.1% in the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company's stock valued at $3,189,000 after acquiring an additional 350,291 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.